Anal incontinence adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From November 2007 to June 2026, FDA received 8,784 adverse event reports that record the MedDRA preferred term Anal incontinence. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 835 reports in the 12 months to June 2026 and 830 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 701 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 835 (0.1%) record this term. Reports for patients 75 and over were 15.7% of the reports that record this term and 9.5% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 107 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Anal incontinence name as a suspect product, in order of name
Drug	Class	Reports with this term
Abilify	Atypical antipsychotic	35
Adalimumab	Tumor necrosis factor blocker	55
Alemtuzumab	CD52-directed cytolytic antibody	26
Alli	Intestinal lipase inhibitor	120
Amlodipine	Calcium channel blocker	52
Ampyra	Potassium channel blocker	67
Aripiprazole	Atypical antipsychotic	29
Aspirin	Nonsteroidal anti-inflammatory drug	43
Aubagio	Pyrimidine synthesis inhibitor	87
Avonex	Interferon beta	55
Azathioprine	Purine antimetabolite	25
Baclofen	gamma-Aminobutyric acid-ergic agonist	44
Bupivacaine	Amide local anesthetic	29
Cabometyx	Kinase inhibitor	27
Capecitabine	Nucleoside metabolic inhibitor	35
Carbidopa levodopa	Aromatic amino acid	63
Carboplatin	Platinum-based drug	37
Ciprofloxacin	Fluoroquinolone antibacterial	34
Clopidogrel	P2Y12 platelet inhibitor	26
Copaxone		38
Cortisone	Corticosteroid	26
Cosentyx	Interleukin-17A antagonist	27
Creon		85
Cytarabine	Nucleoside metabolic inhibitor	30
Dexamethasone	Corticosteroid	50
Donepezil		42
Duodopa		37
Dupixent	Interleukin-4 receptor alpha antagonist	30
Eligard	Gonadotropin releasing hormone receptor agonist	32
Eliquis	Factor Xa inhibitor	32
Enbrel	Tumor necrosis factor blocker	28
Entyvio	Integrin receptor antagonist	90
Escitalopram	Serotonin reuptake inhibitor	38
Fentanyl	Opioid agonist	30
Fluorouracil	Nucleoside metabolic inhibitor	33
Furosemide	Loop diuretic	29
Gabapentin	Anti-epileptic agent	66
Gilenya	Sphingosine 1-phosphate receptor modulator	119
Humira		441
Ibrance	Kinase inhibitor	36
Ibsrela		34
Ibuprofen	Nonsteroidal anti-inflammatory drug	35
Imbruvica	Kinase inhibitor	43
Imodium	Opioid agonist	30
Inflectra	Tumor necrosis factor blocker	98
Infliximab	Tumor necrosis factor blocker	123
Jakafi	Janus kinase inhibitor	33
Kesimpta	CD20-directed cytolytic antibody	51
Levothyroxine		28
Linzess	Guanylate Cyclase-C agonist	129
Lorazepam	Benzodiazepine	30
Lyrica		37
Mesalamine	Aminosalicylate	29
Metformin	Biguanide	105
Metformin hydrochloride	Biguanide	26
Methotrexate	Folate analog metabolic inhibitor	114
Methotrexate sodium	Folate analog metabolic inhibitor	40
MiraLAX	Osmotic laxative	136
Morphine sulfate	Opioid agonist	40
Mounjaro	GLP-1 receptor agonist	41
Nuplazid	Atypical antipsychotic	52
Ocrevus	CD20-directed cytolytic antibody	110
Ofev	Kinase inhibitor	82
Olanzapine	Atypical antipsychotic	44
Omeprazole	Proton pump inhibitor	82
Opsumit	Endothelin receptor antagonist	39
Oxaliplatin	Platinum-based drug	39
Oxycodone	Opioid agonist	31
Oxycodone hydrochloride	Opioid agonist	54
OxyContin	Opioid agonist	39
Ozempic	GLP-1 receptor agonist	66
Pantoprazole	Proton pump inhibitor	35
Pantoprazole sodium	Proton pump inhibitor	41
Polyethylene glycol 3350	Osmotic laxative	54
Prednisolone	Corticosteroid	38
Prednisone	Corticosteroid	97
Pregabalin		32
Quetiapine	Atypical antipsychotic	56
Rebif	Interferon beta	25
Remicade	Tumor necrosis factor blocker	70
Repatha	PCSK9 inhibitor	28
Revlimid	Thalidomide analog	80
Rinvoq	Janus kinase inhibitor	64
Risperidone	Atypical antipsychotic	31
Rituximab	CD20-directed cytolytic antibody	60
Sandostatin	Somatostatin analog	27
Sandostatin LAR Depot		41
Sertraline	Serotonin reuptake inhibitor	49
Simvastatin	HMG-CoA reductase inhibitor	50
Skyrizi	Interleukin-23 antagonist	69
Stelara	Interleukin-12 antagonist	38
SUPREP Bowel Prep	Osmotic laxative	34
Tecfidera		154
Teriflunomide	Pyrimidine synthesis inhibitor	28
Tramadol		35
Trulicity	GLP-1 receptor agonist	33
Tysabri	Integrin receptor antagonist	70
Uptravi	Prostacyclin receptor agonist	39
Valsartan	Angiotensin 2 receptor blocker	36
Vedolizumab	Integrin receptor antagonist	451
Vumerity		39
Xarelto	Factor Xa inhibitor	29
Xeljanz	Janus kinase inhibitor	61
Xtandi	Androgen receptor inhibitor	33
Xyrem	Central nervous system depressant	56
Xywav	Central nervous system depressant	39
Zoledronic acid	Bisphosphonate	31

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 39 pharmacologic classes with 50 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Anal incontinence name, in order of name
Class	Reports with this term
Amide local anesthetic	51
Angiotensin 2 receptor blocker	110
Anti-epileptic agent	130
Aromatic amino acid	79
Atypical antipsychotic	337
Benzodiazepine	91
Biguanide	133
Calcium channel blocker	52
CD20-directed cytolytic antibody	254
Central nervous system depressant	105
Corticosteroid	321
Endothelin receptor antagonist	72
Factor Xa inhibitor	76
Fluoroquinolone antibacterial	55
Folate analog metabolic inhibitor	154
gamma-Aminobutyric acid-ergic agonist	63
GLP-1 receptor agonist	177
Guanylate Cyclase-C agonist	146
HMG-CoA reductase inhibitor	91
Integrin receptor antagonist	612
Interferon beta	112
Interleukin-23 antagonist	73
Intestinal lipase inhibitor	122
Janus kinase inhibitor	160
Kinase inhibitor	358
Nonsteroidal anti-inflammatory drug	121
Nucleoside metabolic inhibitor	118
Opioid agonist	378
Osmotic laxative	254
Platinum-based drug	92
Potassium channel blocker	78
Prostacycline vasodilator	98
Proton pump inhibitor	233
Pyrimidine synthesis inhibitor	115
Serotonin reuptake inhibitor	126
Sodium-Glucose cotransporter 2 inhibitor	58
Sphingosine 1-phosphate receptor modulator	149
Thalidomide analog	109
Tumor necrosis factor blocker	432

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Anal incontinence, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Anal incontinence
Age	Reports	Share
Under 2	10	0.1%
2 to 11	115	1.3%
12 to 17	54	0.6%
18 to 44	986	11.2%
45 to 64	1,939	22.1%
65 to 74	1,400	15.9%
75 and over	1,380	15.7%
Age not given	2,900	33%

Sex of the patient in the reports that record Anal incontinence
Sex	Reports	Share
Female	5,095	58%
Male	2,882	32.8%
Unknown or not given	807	9.2%

Age and sex are as the report gives them. 55.7% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Anal incontinence: adverse event reports that record this term. https://reportedreactions.com/reaction/anal-incontinence/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Anal incontinence mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page